Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL823290 | 0.79 | ALDH1A1 (0.39) | ALDH1A1TSHRDNM1HTR2AHRH1 | |
| SCHEMBL14961089 | 0.76 | ALDH1A1 (0.41) | ALDH1A1TSHRDNM1HTR2AHRH1 | |
| SCHEMBL13009538 | 0.76 | ALDH1A1 (0.36) | ALDH1A1TSHRDNM1HTR2AHRH1 | |
| SCHEMBL27804669 | 0.76 | ALDH1A1 (0.36) | ALDH1A1TSHRDNM1HTR2AHRH1 | |
| SCHEMBL21906463 | 0.76 | ALDH1A1 (0.36) | ALDH1A1TSHRDNM1HTR2AHRH1 | |
| SCHEMBL3315106 | 0.75 | — | — | |
| SCHEMBL18106104 | 0.73 | OPRM1 (0.52) | ALDH1A1TSHRDNM1LMNATHRB | |
| SCHEMBL610212 | 0.73 | OPRM1 (0.52) | ALDH1A1TSHRDNM1LMNATHRB | |
| SCHEMBL2737161 | 0.73 | LMNA (0.43) | LMNATHRB | |
| SCHEMBL19566344 | 0.73 | ALDH1A1 (0.43) | ALDH1A1TSHRDNM1HTR2AHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002316-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2023-01-05 | — | — | US | disclosed |
| US-7264678-B2 | Process for cleaning a surface | THE PROCTER & GAMBLE COMPANY (US) | 2007-09-04 | — | — | US | disclosed |
| US-20070093407-A1 | Process of treating fabrics | THE PROCTER & GAMBLE COMPANY (US) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002316-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | NR1H4, HCAR3, VDR | ALDH1A1 2916/4885TSHR 703/4885DNM1 2380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.